Bifogade filer
Kurs
-9,66%
Likviditet
0,58 MSEK
Kalender
Tid* | ||
2025-11-20 | N/A | Årsstämma |
2025-11-14 | 09:00 | Kvartalsrapport 2026-Q1 |
2025-08-28 | 08:30 | Bokslutskommuniké 2025 |
2025-05-22 | 09:00 | Kvartalsrapport 2025-Q3 |
2025-02-13 | 09:00 | Kvartalsrapport 2025-Q2 |
2024-11-22 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
2024-11-21 | - | Årsstämma |
2024-11-15 | - | Kvartalsrapport 2025-Q1 |
2024-08-28 | - | Bokslutskommuniké 2024 |
2024-05-24 | - | Kvartalsrapport 2024-Q3 |
2024-02-22 | - | Kvartalsrapport 2024-Q2 |
2023-12-14 | - | Extra Bolagsstämma 2024 |
2023-11-24 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
2023-11-23 | - | Årsstämma |
2023-11-17 | - | Kvartalsrapport 2024-Q1 |
2023-08-28 | - | Bokslutskommuniké 2023 |
2023-05-26 | - | Kvartalsrapport 2023-Q3 |
2023-05-17 | - | Extra Bolagsstämma 2023 |
2023-02-23 | - | Kvartalsrapport 2023-Q2 |
2022-11-25 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
2022-11-24 | - | Årsstämma |
2022-11-11 | - | Kvartalsrapport 2023-Q1 |
2022-08-26 | - | Bokslutskommuniké 2022 |
2022-05-20 | - | Kvartalsrapport 2022-Q3 |
2022-02-25 | - | Kvartalsrapport 2022-Q2 |
2021-11-26 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
2021-11-25 | - | Årsstämma |
2021-11-11 | - | Kvartalsrapport 2022-Q1 |
2021-08-27 | - | Bokslutskommuniké 2021 |
2021-06-17 | - | Extra Bolagsstämma 2022 |
2021-05-21 | - | Kvartalsrapport 2021-Q3 |
2021-03-02 | - | Extra Bolagsstämma 2021 |
2021-02-26 | - | Kvartalsrapport 2021-Q2 |
2020-11-27 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
2020-11-26 | - | Årsstämma |
2020-11-12 | - | Kvartalsrapport 2021-Q1 |
2020-08-28 | - | Bokslutskommuniké 2020 |
2020-05-22 | - | Kvartalsrapport 2020-Q3 |
2020-02-28 | - | Kvartalsrapport 2020-Q2 |
2019-11-22 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
2019-11-21 | - | Årsstämma |
2019-11-08 | - | Kvartalsrapport 2020-Q1 |
2019-08-30 | - | Bokslutskommuniké 2019 |
2019-05-17 | - | Kvartalsrapport 2019-Q3 |
2019-02-15 | - | Kvartalsrapport 2019-Q2 |
2018-11-16 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
2018-11-15 | - | Årsstämma |
2018-11-09 | - | Kvartalsrapport 2019-Q1 |
2018-08-30 | - | Bokslutskommuniké 2018 |
2018-05-18 | - | Kvartalsrapport 2018-Q3 |
2018-02-16 | - | Kvartalsrapport 2018-Q2 |
2017-11-10 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
2017-11-09 | - | Årsstämma |
2017-11-02 | - | Kvartalsrapport 2018-Q1 |
2017-08-18 | - | Bokslutskommuniké 2017 |
2017-05-12 | - | Kvartalsrapport 2017-Q3 |
2017-02-10 | - | Kvartalsrapport 2017-Q2 |
2017-01-19 | - | Extra Bolagsstämma 2018 |
2016-11-18 | - | Kvartalsrapport 2017-Q1 |
2016-11-11 | - | X-dag ordinarie utdelning HAMLET B 0.00 SEK |
2016-11-10 | - | Årsstämma |
2016-08-19 | - | Bokslutskommuniké 2016 |
2016-05-13 | - | Kvartalsrapport 2016-Q3 |
2016-02-12 | - | Kvartalsrapport 2016-Q2 |
2015-11-13 | - | Kvartalsrapport 2016-Q1 |
Beskrivning
Land | Sverige |
---|---|
Lista | Spotlight |
Sektor | Hälsovård |
Industri | Bioteknik |
Hamlet BioPharma, the innovative pharmaceutical company currently advancing several phase II trials targeting infectious diseases and cancer, along with an extensive project and patent portfolio, is delighted to announce the webinar, hosted by MSQ ventures in the MSQ's CEO Webinar series, released during the JP Morgan Health Care Conference 2024, this week.
[image]
Register in advance for this webinar:
https://us02web.zoom.us/webinar/register/WN_VbVV8FrXTYmtyOF16AmWWw
MSQ Ventures and BioAroundWorld are collaborating to host a bi-weekly MSQ CEO Webinar Series targeting strategic partners and financial investors from the global-regional biopharma community. The webinar aims to promote knowledge-sharing and networking among participants by featuring CEOs who will present their companies' clinical pipeline's value proposition, differentiation, and upcoming milestones. The primary objective of the webinar is to enhance the visibility of participating companies fostering global-regional biopharma collaborative opportunities.
About Hamlet Biopharma
Hamlet Biopharma is an innovative pharmaceutical company with a broad and strong portfolio of projects for the treatment of cancer and infections. The company is listed on Spotlight Stockmarket in Stockholm, Sweden, under the ticker HAMLET.
Read more about the company and the portfolio of drug candidates at www.hamletbiopharma.com.
For further information, please contact:
Catharina Svanborg, Chairman and Founder of Hamlet BioPharma, +46-709 42 65 49
catharina.svanborg@hamletpharma.com
Martin Erixon, CEO Hamlet BioPharma, +46-733 00 43 77
martin.erixon@hamletpharma.com
www.hamletbiopharma.com